Busulfan in hematopoietic stem cell transplant setting

Expert Opinion on Drug Metabolism and Toxicology

Volumn 5, Issue 8, 2009, Pages 957-969

  McCune, Jeannine S ^a   Holmberg, Leona A ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

Busulfan; Busulfan pharmacodynamics; Busulfan pharmacogenomics; Busulfan pharmacokinetics; Drug monitoring; Hematopoietic stem cell transplant

Indexed keywords

BUSULFAN; CLONAZEPAM; CYCLOPHOSPHAMIDE; ETIRACETAM; FLUDARABINE; GLUTATHIONE TRANSFERASE M1; GLUTATHIONE TRANSFERASE P1; GLUTATHIONE TRANSFERASE T1; LORAZEPAM; PHENYTOIN; TREOSULFAN; URSODEOXYCHOLIC ACID;

ABDOMINAL PAIN; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANOREXIA; ANXIETY; AREA UNDER THE CURVE; ASTHENIA; BACKACHE; CHILL; CHOLESTATIC HEPATITIS; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; CONSTIPATION; COUGHING; CYTOTOXICITY; DIARRHEA; DIZZINESS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CEREBROSPINAL FLUID LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE REGIMEN; DRUG ELIMINATION; DRUG ERUPTION; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG MONITORING; DRUG POTENTIATION; DYSPEPSIA; DYSPNEA; EDEMA; EPISTAXIS; GENETIC POLYMORPHISM; GRAFT REJECTION; HEADACHE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HYPERBILIRUBINEMIA; HYPERGLYCEMIA; HYPERTENSION; HYPOCALCEMIA; HYPOKALEMIA; HYPOMAGNESEMIA; INFERTILITY; INJECTION PAIN; INJECTION SITE INFLAMMATION; INSOMNIA; LIVER TOXICITY; LIVER VEIN OBSTRUCTION; LUNG DISEASE; LUNG FIBROSIS; METASTASIS; MUCOSA INFLAMMATION; MYELOABLATIVE CONDITIONING; NAUSEA AND VOMITING; OBESITY; PHARMACOGENOMICS; PRURITUS; RECTUM DISEASE; RETROPERITONEAL FIBROSIS; REVIEW; RHINITIS; SEIZURE; SIDE EFFECT; STOMATITIS; TACHYCARDIA; THORAX PAIN; THROMBOSIS; VASODILATATION; VASODILATUION; XEROSTOMIA;

ADULT; BUSULFAN; CHILD; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; PHARMACOGENETICS;

EID: 68149171619     PISSN: 17425255     EISSN: None     Source Type: Journal    
DOI: 10.1517/17425250903107764     Document Type: Review

References (99)

1. DeLeve LD, Wang X. Role of oxidative stress and glutathione in busulfan toxicity in cultured murine hepatocytes. Pharmacology 2000;60:143-154 (Pubitemid 30189528)
2. Czerwinski M, Gibbs JP, Slattery JT. Busulfan conjugation by glutathione S-transferases alpha, mu, and pi. Drug Metab Dispos 1996;24(9):1015-1019 (Pubitemid 26314555)
3. Gibbs JP, Liacouras CA, Baldassano RN, Slattery JT. Up-regulation of glutathione S-transferase activity in enterocytes of young children. Drug Metab Dispos 1999;27(12):1466-1469
4. McCune JS, Gibbs JP, Slattery JT. Plasma concentration monitoring of busulfan: does it improve clinical outcome? Clin Pharmacokinet 2000;39(2):155-165
5. Vassal G, Gouyette A, Hartmann O, et al. Pharmacokinetics of high-dose busulfan in children. Cancer Chemother Pharmacol 1989;24(6):386-390
6. Hassan M, Ehrsson H, Smedmyr B, et al. Cerebrospinal fluid and plasma concentrations of busulfan during high- dose therapy. Bone Marrow Transplant 1989;4(1):113-114 (Pubitemid 19064916)
7. Nguyen L, Fuller D, Lennon S, et al. I.V. busulfan in pediatrics: a novel dosing to improve safety/efficacy for hematopoietic progenitor cell transplantation recipients. Bone Marrow Transplant 2004;33(10):979-987 (Pubitemid 38744783)
8. Schechter T, Finkelstein Y, Doyle J, et al. Pharmacokinetic disposition and clinical outcomes in infants and children receiving intravenous busulfan for allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2007;13(3):307-314 (Pubitemid 46268257)
9. Eberly AL, Anderson GD, Bubalo JS, McCune JS. Optimal prevention of seizures induced by high-dose busulfan. Pharmacotherapy 2008;28(12):1502-1510
10. Gibbs JP, Gooley T, Corneau B, et al. The impact of obesity and disease on busulfan oral clearance in adults. Blood 1999;93(12):4436-4440 (Pubitemid 29279287)
11. Ryu SG, Lee JH, Choi SJ, et al. Randomized comparison of four-times-daily versus once-daily intravenous busulfan in conditioning therapy for hematopoietic cell transplantation. Biol Blood Marrow Transplant 2007;13(9):1095-1105
12. Geddes M, Kangarloo SB, Naveed F, et al. High busulfan exposure is associated with worse outcomes in a daily i.v. busulfan and fludarabine allogeneic transplant regimen. Biol Blood Marrow Transplant 2008;14(2):220-228
13. Vassal G, Michel G, Esperou H, et al. Prospective validation of a novel IV busulfan fixed dosing for paediatric patients to improve therapeutic AUC targeting without drug monitoring. Cancer Chemother Pharmacol 2008;61(1):113-123 (Pubitemid 47512633)
14. Andersson BS, Thall PF, Madden T, et al. Busulfan systemic exposure relative to regimen-related toxicity and acute graft-versus-host disease: defining a therapeutic window for i.v. BuCy2 in chronic myelogenous leukemia. Biol Blood Marrow Transplant 2002;8(9):477-485
15. Das P, Doyle J, Dupuis LL. Appropriate busulfan dosing. Bone Marrow Transplant 2005;35(2):199-200
16. Gibbs JP, Murray G, Risler L, et al. Age-dependent tetrahydrothiophenium ion formation in young children and adults receiving high-dose busulfan. Cancer Res 1997;57(24):5509-5516 (Pubitemid 28006757)
17. Takama H, Tanaka H, Nakashima D, et al. Population pharmacokinetics of intravenous busulfan in patients undergoing hematopoietic stem cell transplantation. Bone Marrow Transplant 2006;37(4):345-351 (Pubitemid 43250467)
18. Zwaveling J, Bredius RG, Cremers SC, et al. Intravenous busulfan in children prior to stem cell transplantation: study of pharmacokinetics in association with early clinical outcome and toxicity. Bone Marrow Transplant 2005;35(1):17-23 (Pubitemid 40090051)
19. Cremers S, Schoemaker R, Bredius R, et al. Pharmacokinetics of intravenous busulfan in children prior to stem cell transplantation. Br J Clin Pharmacol 2002;53(4):386-389 (Pubitemid 34415589)
20. Murry DJ, Crom WR, Reddick WE, et al. Liver volume as a determinant of drug clearance in children and adolescents. Drug Metab Dispos 1995;23(10):1110-1116
21. Nguyen L, Leger F, Lennon S, Puozzo C. Intravenous busulfan in adults prior to haematopoietic stem cell transplantation: a population pharmacokinetic study. Cancer Chemother Pharmacol 2006;57(2):191-198 (Pubitemid 41779838)
22. Bertholle-Bonnet V, Bleyzac N, Galambrun C, et al. Influence of underlying disease on busulfan disposition in pediatric bone marrow transplant recipients: a nonparametric population pharmacokinetic study. Ther Drug Monit 2007;29(2):177-184 (Pubitemid 46716183)
23. Bredschneider M, Klein K, Murdter TE, et al. Genetic polymorphisms of glutathione S-transferase A1, the major glutathione S-transferase in human liver: consequences for enzyme expression and busulfan conjugation. Clin Pharmacol Ther 2002;71(6):479-487 (Pubitemid 34701355)
24. Zwaveling J, Press RR, Bredius RG, et al. Glutathione S-transferase polymorphisms are not associated with population pharmacokinetic parameters of busulfan in pediatric patients. Ther Drug Monit 2008;30(4):504-510
25. Johnson L, Orchard PJ, Baker KS, et al. Glutathione S-Transferase a1 genetic variants reduce busulfan clearance in children undergoing hematopoietic cell transplantation. J Clin Pharmacol 2008;48(9):1052-1062
26. Kusama M, Kubota T, Matsukura Y, et al. Influence of glutathione S-transferase A1 polymorphism on the pharmacokinetics of busulfan. Clin Chim Acta 2006;368(1-2):93-98 (Pubitemid 43776023)
27. Srivastava A, Poonkuzhali B, Shaji RV, et al. Glutathione S-transferase M1 polymorphism: a risk factor for hepatic venoocclusive disease in bone marrow transplantation. Blood 2004;104(5):1574-1577 (Pubitemid 39166540)
28. McLeod HL. Therapeutic drug monitoring opportunities in cancer therapy. Pharmacol Ther 1997;74(1):39-54 (Pubitemid 27337353)
29. Slattery JT, Risler LJ. Therapeutic monitoring of busulfan in hematopoietic stem cell transplantation. Ther Drug Monit 1998;20(5):543-549 (Pubitemid 28463447)
30. Tran H, Petropoulos D, Worth L, et al. Pharmacokinetics and individualized dose adjustment of intravenous busulfan in children with advanced hematologic malignancies undergoing allogeneic stem cell transplantation. Biol Blood Marrow Transplant 2004;10(11):805-812 (Pubitemid 39406769)
31. Dix SP, Wingard JR, Mullins RE, et al. Association of busulfan area under the curve with veno-occlusive disease following BMT. Bone Marrow Transplant 1996;17(2):225-230
32. Fisher VL, Barnes YJ, Nuss SL. Pretransplant conditioning in adults and children: dose assurance with intravenous busulfan. Oncol Nurs Forum 2006;33(2):E36-43
33. Lindley C, Shea T, McCune J, et al. Intraindividual variability in busulfan pharmacokinetics in patients undergoing a bone marrow transplant: assessment of a test dose and first dose strategy. Anticancer Drugs 2004;15(5):453-459 (Pubitemid 38736942)
34. Horn B, Baxter-Lowe LA, Englert L, et al. Reduced intensity conditioning using intravenous busulfan, fludarabine and rabbit ATG for children with nonmalignant disorders and CML. Bone Marrow Transplant 2006;37(3):263-269
35. Kletzel M, Jacobsohn D, Duerst R. Pharmacokinetics of a test dose of intravenous busulfan guide dose modifications to achieve an optimal area under the curve of a single daily dose of intravenous busulfan in children undergoing a reduced-intensity conditioning regimen with hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2006;12(4):472-479 (Pubitemid 43380964)
36. Balasubramanian P, Chandy M, Krishnamoorthy R, Srivastava A. Evaluation of existing limited sampling models for busulfan kinetics in children with beta thalassaemia major undergoing bone marrow transplantation. Bone Marrow Transplant 2001;28(9):821-825 (Pubitemid 33107608)
37. Sandstrom M, Karlsson MO, Ljungman P, et al. Population pharmacokinetic analysis resulting in a tool for dose individualization of busulphan in bone marrow transplantation recipients. Bone Marrow Transplant 2001;28(7):657-664 (Pubitemid 33014599)
38. Vaughan WP, Carey D, Perry S, et al. A limited sampling strategy for pharmacokinetic directed therapy with intravenous busulfan. Biol Blood Marrow Transplant 2002;8(11):619-624 (Pubitemid 35446753)
39. Dupuis LL, Sibbald C, Schechter T, et al. IV busulfan dose individualization in children undergoing hematopoietic stem cell transplant: limited sampling strategies. Biol Blood Marrow Transplant 2008;14(5):576-582
40. Bleyzac N, Souillet G, Magron P, et al. Improved clinical outcome of paediatric bone marrow recipients using a test dose and Bayesian pharmacokinetic individualization of busulfan dosage regimens. Bone Marrow Transplant 2001;28(8):743-751 (Pubitemid 33089217)
41. Bullock JM, Smith PF, Booker BM, et al. Development of a pharmacokinetic and Bayesian optimal sampling model for individualization of oral busulfan in hematopoietic stem cell transplantation. Ther Drug Monit 2006;28(1):62-66
42. Nakamura H, Sato T, Okada K, et al. Population pharmacokinetics of oral busulfan in young Japanese children before hematopoietic stem cell transplantation. Ther Drug Monit 2008;30(1):75-83 (Pubitemid 351161102)
43. Booth BP, Rahman A, Dagher R, et al. Population pharmacokinetic-based dosing of intravenous busulfan in pediatric patients. J Clin Pharmacol 2007;47(1):101-111 (Pubitemid 44974004)
44. Olavarria E, Kanfer E, Szydlo R, et al. High-dose busulphan alone as cytoreduction before allogeneic or autologous stem cell transplantation for chronic myeloid leukaemia: a single-centre experience. Br J Haematol 2000;108(4):769-777 (Pubitemid 30304509)
45. Vassal G, Deroussent A, Hartmann O, et al. Dose-dependent neurotoxicity of high-dose busulfan in children: a clinical and pharmacological study. Cancer Res 1990;50(19):6203-6207 (Pubitemid 20323675)
46. Meloni G, Raucci U, Pinto RM, et al. Pretransplant conditioning with busulfan and cyclophosphamide in acute leukemia patients: neurological and electroencephalographic prospective study. Ann Oncol 1992;3(2):145-148
47. Murphy CP, Harden EA, Thompson JM. Generalized seizures secondary to high-dose busulfan therapy. Ann Pharmacother 1992;26(1):30-31
48. Davies MH, Schnell RC. Comparison of basal glutathione S-transferase activities and of the influence of phenobarbital, butylated hydroxy-anisole or 5,5′-diphenylhydantoin on enzyme activity in male rodents. Comp Biochem Physiol C 1987;88(1):91-93
49. Fitzsimmons WE, Ghalie R, Kaizer H. The effect of hepatic enzyme inducers on busulfan neurotoxicity and myelotoxicity. Cancer Chemother Pharmacol 1990;27(3):226-228
50. Gallagher EP, Sheehy KM. Effects of phenytoin on glutathione status and oxidative stress biomarker gene mRNA levels in cultured precision human liver slices. Toxicol Sci 2001;59(1):118-126
51. Aggarwal C, Gupta S, Vaughan WP, et al. Improved outcomes in intermediate- and high-risk aggressive non-Hodgkin lymphoma after autologous hematopoietic stem cell transplantation substituting intravenous for oral busulfan in a busulfan, cyclophosphamide, and etoposide preparative regimen. Biol Blood Marrow Transplant 2006;12(7):770-777 (Pubitemid 43899416)
52. Madden T, de Lima M, Thapar N, et al. Pharmacokinetics of once-daily IV busulfan as part of pretransplantation preparative regimens: a comparison with an every 6-hour dosing schedule. Biol Blood Marrow Transplant 2007;13(1):56-64 (Pubitemid 46044090)
53. Chan KW, Mullen CA, Worth LL, et al. Lorazepam for seizure prophylaxis during high-dose busulfan administration. Bone Marrow Transplant 2002;29(12):963-965
54. Bubalo JS, Kovascovics TJ, Meyers G, et al. Clonazepam Plus Levetiracetam (CL) for the prevention of busulfan-induced seizures: a single center experience. Biol Blood Marrow Transplant 2008;14(2):165(abstract#467)
55. Ringdén O, Labopin M, Tura S, et al. A comparison of busulphan versus total body irradiation combined with cyclophosphamide as conditioning for autograft or allograft bone marrow transplantation in patients with acute leukaemia. Acute leukaemia working party of the European Group for Blood and Marrow Transplantation (EBMT). Br J Haematol 1996;93(3):637-645
56. Kashyap A, Wingard J, Cagnoni P, et al. Intravenous versus oral busulfan as part of a busulfan/cyclophosphamide preparative regimen for allogeneic hematopoietic stem cell transplantation: decreased incidence of hepatic venoocclusive disease (HVOD), HVOD-related mortality, and overall 100-day mortality. Biol Blood Marrow Transplant 2002;8(9):493-500 (Pubitemid 35174823)
57. Lee JH, Choi SJ, Lee JH, et al. Decreased incidence of hepatic veno-occlusive disease and fewer hemostatic derangements associated with intravenous busulfan vs oral busulfan in adults conditioned with busulfan + cyclophosphamide for allogeneic bone marrow transplantation. Ann Hematol 2005;84(5):321-330
58. McCune JS, Batchelder A, Deeg HJ, et al. Cyclophosphamide following targeted oral busulfan as conditioning for hematopoietic cell transplantation: pharmacokinetics, liver toxicity, and mortality. Biol Blood Marrow Transplant 2007;13(7):853-862 (Pubitemid 46902444)
59. Williams CB, Day SD, Reed MD, et al. Dose modification protocol using intravenous busulfan (Busulfex) and cyclophosphamide followed by autologous or allogeneic peripheral blood stem cell transplantation in patients with hematologic malignancies. Biol Blood Marrow Transplant 2004;10(9):614-623
60. Slattery JT. Re: intravenous versus oral busulfan-perhaps not as different as suggested. Biol Blood Marrow Transplant 2003;9(4):282-284
61. Andersson BS, Kashyap A, Couriel D, et al. Intravenous busulfan in pretransplant chemotherapy: bioavailability and patient benefit. Biol Blood Marrow Transplant 2003;9(11):722-724 (Pubitemid 38145756)
62. Brice K, Valerie B, Claire G, et al. Risk-adjusted monitoring of veno-occlusive disease following Bayesian individualization of busulfan dosage for bone marrow transplantation in paediatrics. Pharmacoepidemiol Drug Saf 2008;17(2):135-143 (Pubitemid 351308512)
63. Grochow LB. Busulfan disposition: the role of therapeutic monitoring in bone marrow transplantation induction regimens. Semin Oncol 1993;20(4 Suppl 4):18-25; quiz 26
64. Chang C, Storer BE, Scott BL, et al. J. Hematopoietic cell transplantation in patients with myelodysplastic syndrome or acute myeloid leukemia arising from myelodysplastic syndrome: similar outcomes in patients with de novo disease and disease following prior therapy or antecedent hematologic disorders. Blood 2007;110(4):1379-1387 (Pubitemid 47281440)
65. DeLeve LD. Cellular target of cyclophosphamide toxicity in the murine liver: role of glutathione and site of metabolic activation. Hepatology 1996;24(4):830-837
66. McCune JS, Bachelder A, Guthrie KA, et al. Personalized dosing of cyclophosphamide in the total body irradiation-cyclophosphamide conditioning regimen: a phase II trial in patients with hematologic malignancy. Clin Pharmacol Ther 2009;85(6):615-622
67. Essell JH, Schroeder MT, Harman GS, et al. Ursodiol prophylaxis against hepatic complications of allogeneic bone marrow transplantation. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1998;128(12 Pt 1):975-981
68. Tay J, Tinmouth A, Fergusson D, et al. Systematic review of controlled clinical trials on the use of ursodeoxycholic acid for the prevention of hepatic veno-occlusive disease in hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2007;13(2):206-217 (Pubitemid 46115719)
69. Kennedy D, Holmberg L. Incidence of liver dysfunction since the initiation of ursodiol prophylaxis in autologous transplant patients. American Society of Health-System Pharmacists 39th Midyear Clinical Meeting, 2004
70. Hassan M, Ljungman P, Ringden O, et al. The effect of busulphan on the pharmacokinetics of cyclophosphamide and its 4-hydroxy metabolite: time interval influence on therapeutic efficacy and therapy-related toxicity. Bone Marrow Transplant 2000;25(9):915-924 (Pubitemid 30255722)
71. Nilsson C, Forsman J, Hassan Z, et al. Effect of altering administration order of busulphan and cyclophosphamide on the myeloablative and immunosuppressive properties of the conditioning regimen in mice. Exp Hematol 2005;33(3):380-387 (Pubitemid 40261320)
72. Meresse V, Hartmann O, Vassal G, et al. Risk factors for hepatic veno-occlusive disease after high-dose busulfan-containing regimens followed by autologous bone marrow transplantation: a study in 136 children. Bone Marrow Transplant 1992;10(2):135-141
73. Fernandez HF, Tran HT, Albrecht F, et al. Evaluation of safety and pharmacokinetics of administering intravenous busulfan in a twice-daily or daily schedule to patients with advanced hematologic malignant disease undergoing stem cell transplantation. Biol Blood Marrow Transplant 2002;8(9):486-492 (Pubitemid 35174822)
74. Matthews RH, Emami M, Connaghan DG, et al. Home administration of high-dose Busulfan in patients undergoing hematopoietic stem cell transplantation. Bone Marrow Transplant 2007;39:397-400 (Pubitemid 46487304)
75. Chandy M, Balasubramanian P, Ramachandran SV, et al. Randomized trial of two different conditioning regimens for bone marrow transplantation in thalassemia-the role of busulfan pharmacokinetics in determining outcome. Bone Marrow Transplant 2005;36(10):839-845 (Pubitemid 41655608)
76. Slattery JT, Clift RA, Buckner CD, et al. Marrow transplantation for chronic myeloid leukemia: the influence of plasma busulfan levels on the outcome of transplantation. Blood 1997;89(8):3055-3060
77. Radich JP, Gooley T, Bensinger W, et al. HLA-matched related hematopoietic cell transplantation for chronic-phase CML using a targeted busulfan and cyclophosphamide preparative regimen. Blood 2003;102(1):31-35 (Pubitemid 36759632)
78. Deeg HJ, Storer B, Slattery JT, et al. Conditioning with targeted busulfan and cyclophosphamide for hemopoietic stem cell transplantation from related and unrelated donors in patients with myelodysplastic syndrome. Blood 2002;100(4):1201-1207 (Pubitemid 34864272)
79. Deeg HJ, Gooley TA, Flowers MED, et al. Allogeneic hematopoietic stem cell transplantation for myelofibrosis. Blood 2003;102(12):3912-3918 (Pubitemid 37486970)
80. Russell JA, Tran HT, Quinlan D, et al. Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: study of pharmacokinetics and early clinical outcomes. Biol Blood Marrow Transplant 2002;8(9):468-476 (Pubitemid 35174820)
81. Bornhauser M, Storer B, Slattery JT, et al. Conditioning with fludarabine and targeted busulfan for transplantation of allogeneic hematopoietic stem cells. Blood 2003;102(3):820-826 (Pubitemid 36917770)
82. de Lima M, Couriel D, Thall PF, et al. Once-daily intravenous busulfan and fludarabine: clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS. Blood 2004;104(3):857-864 (Pubitemid 38970585)
83. Gandhi V, Plunkett W. Cellular and clinical pharmacology of fludarabine. Clin Pharmacokinet 2002;41(2):93-103
84. Altman J, Venepalli N, Monreal J, et al. Oral busulfan and cyclophosphamide or IV busulfan and fludarabine for allogeneic HSCT in hematologic malignancies? Blood 2006;108(11):(abstract#2940)
85. Andersson BS, de Lima M, Thall PF, et al. Once daily i.v. busulfan and fludarabine (i.v. Bu-Flu) compares favorably with i.v. busulfan and cyclophosphamide (i.v. BuCy2) as pretransplant conditioning therapy in AML/MDS. Biol Blood Marrow Transplant 2008;14(6):672-684 (Pubitemid 351664062)
86. Jenke A, Freiberg-Richter J, Johne C, et al. Targeting once-daily intravenous busulfan in combination with fludarabine before allogeneic hematopoietic cell transplantation. Bone Marrow Transplant 2005;35(6):627-628 (Pubitemid 40450465)
87. Naveed F, Kangarloo S, Chaudhry A, et al. Improving the pharmacokinetic analysis of the once daily IV busulfan regimen for allogeneic stem-cell transplants: a scientific method modification. Blood 2006;108(11): (abstract#2941)
88. Field T, Perkins J, Alsina M, et al. Busulfan area-under-the-curve finding study within a busulfan/fludarabine (BuFlu) conditioning regimen before allogeneic hematopoietic cell transplantation (HCT). Blood 2006;108(11): (abstract#2939)
89. Schuler US, Renner UD, Kroschinsky F, et al. Intravenous busulphan for conditioning before autologous or allogeneic human blood stem cell transplantation. Br J Haematol 2001;114(4):944-950 (Pubitemid 32953759)
90. Glowka FK, Karazniewicz-Lada M, Grund G, et al. Pharmacokinetics of high-dose i.v. treosulfan in children undergoing treosulfan-based preparative regimen for allogeneic haematopoietic SCT. Bone Marrow Transplantation 2008;42(2):S67-70
91. Schmidmaier R, Oellerich M, Baumgart J, et al. Treosulfan-induced apoptosis in acute myeloid leukemia cells is accompanied by translocation of protein kinase C delta and enhanced by bryostatin-1. Exp Hematol 2004;32(1):76-86 (Pubitemid 38064404)
92. Ploemacher RE, Johnson KW, Rombouts EJ, et al. Addition of treosulfan to a nonmyeloablative conditioning regimen results in enhanced chimerism and immunologic tolerance in an experimental allogeneic bone marrow transplant model. Biol Blood Marrow Transplant 2004;10(4):236-245
93. Casper J, Knauf W, Kiefer T, et al. Treosulfan and fludarabine: a new toxicity-reduced conditioning regimen for allogeneic hematopoietic stem cell transplantation. Blood 2004;103(2):725-731 (Pubitemid 38140111)
94. Shimoni A, Hardan I, Shem-Tov N, et al. Fludarabine and treosulfan: a novel modified myeloablative regimen for allogeneic hematopoietic stem-cell transplantation with effective antileukemia activity in patients with acute myeloid leukemia and myelodysplastic syndromes. Leuk Lymphoma 2007;48(12):2352-2359 (Pubitemid 350258301)
95. Kröger N, Shimoni A, Zabelina T, et al. Reduced-toxicity conditioning with treosulfan, fludarabine and ATG as preparative regimen for allogeneic stem cell transplantation (alloSCT) in elderly patients with secondary acute myeloid leukemia (sAML) or myelodysplastic syndrome (MDS). Bone Marrow Transplant 2006;37(4):339-344
96. Baronciani D, Rambaldi A, Iori AP, et al. Treosulfan/fludarabine as an allogeneic hematopoietic stem cell transplant conditioning regimen for high-risk patients. Am J Hematol 2008;83(9):717-720
97. Bernardo ME, Zecca M, Piras E, et al. Treosulfan-based conditioning regimen for allogeneic haematopoietic stem cell transplantation in patient with thalassaemia major. Br J Haematol 2008;143(4):548-551
98. Blau IW, Schmidt-Hieber M, Leschinger N, et al. Engraftment kinetics and hematopoietic chimerism after reduced-intensity conditioning with fludarabine and treosulfan before allogeneic stem cell transplantation. Ann Hematol 2007;86(8):583-589 (Pubitemid 47022827)
99. Schmidt-Hieber M, Blau IW, Trenschel R, et al. Reduced-toxicity conditioning with fludarabine and treosulfan prior to allogeneic stem cell transplantation in multiple myeloma. Bone Marrow Transplantation 2007;39(7):389-396 (Pubitemid 46487303)